A Comparative Pharmaco-Clinical Study of Arjuna and Manjishtha w.s.r. to Vyanga

2019 ◽  
Vol 4 (04) ◽  
Author(s):  
Kamayani Mishra ◽  
Umesh Shukla ◽  
K. C. Garg ◽  
Shraddha Sharma
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Drug Administration ◽  
Psychological Factors ◽  
Skin Diseases ◽  
Point Of View ◽  
Facial Skin ◽  
Skin Disorders

In Ayurveda Vyanga is a disease which is firstly described by Acharya Sushruta under Kshudra Roga. According to Acharya Sushruta Krodha and Shoka are responsible for development of Vyanga, as these psychological factors vitiate Pitta and Vata Dosha which then travel and get localized on facial skin and leads to development of Nirujam, Tanu Shyava Varna Mandala. Ayurveda is very effective in treating skin disorders and skin is also mentioned as a route of drug administration in terms of Bahiparimarajan Chikitsa. Acharya Sharangdhara has mentioned various Lepa formulations for various skin diseases; among them he has quoted Arjuna Twak Churna and Manjishtha Churna for treatment of Vyanga. It is easy to understand about Manjishtha because it is a very well known established Varnya drug, but regarding Arjuna it was very much important to trail it clinically as it is an established drug for heart. From Dravyaguna point of view it was very important to study Arjuna, that how it would have broken the pathogenesis of Vyanga, what are the major chemicals present in Arjuna that work on hyper pigmentation. So a proper revalidation of Shastrokta quote of Acharya Sharangdhara was done by clinical trial and pharmacognostical and HPTLC analysis of Arjuna and Manjishtha.

scholarly journals CONTROLLED RANDOMIZED CLINICAL TRIAL ON USING TALISADI TAILAM FOR TREATING PATIENTS OF TINEA PEDIS W.S.R TO ALASA

AYUSHDHARA ◽  
2021 ◽  
pp. 3104-3108
Author(s):  
Gupta Sudesh ◽  
Manhas Raman, Prasher Aarushi, Sharma Sakshi, Sharma Arun
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Fungal Infection ◽  
Tinea Pedis ◽  
External Surface ◽  
Signs And Symptoms ◽  
The Body ◽  
Skin Disorders ◽  
Before And After ◽  
Athlete’S Foot

Skin is the general covering of the entire external surface of the body. Because of a large number of its functions, the skin is regarded as an important organ of the body. There are so many skin disorders of which Tenia pedis is a very common fungal infection that affects a significantly large number of people globally. This fungal infection is called Athlete’s foot because it is commonly seen in athletes. In Ayurveda, various skin disorders are described under the heading of kshudraroga. A brief description about Kshudraroga has been given in many Ayurvedic classics. Alasa is a variety of Kshudraroga occurring in between the skin of toes manifesting with Kleda, Kandu, Daha and Ruja. Talisadi tailam mentioned in Sushruta Samhita is an excellent formulation prepared of drugs which are effective against this disease. Current study includes 30 patients from OPD Department of Shalya Tantra, Jammu Institute of Ayurveda and Research, Jammu and Sri Sain Charitable Hospital, Janipur, Jammu diagnosed to have Tenia pedis based on signs and symptoms. Therapeutic effect was evaluated before and after treatment. The present clinical study has shown symptoms of Kandu, Daha, Ruja, Kleda significantly reduced after application of Talisadi tailam.

The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review

2019 ◽  
Vol 14 (1) ◽  
pp. 22-33 ◽  
Author(s):  
Ali Golchin ◽  
Tahereh Z. Farahany ◽  
Arash Khojasteh ◽  
Fatemeh Soleimanifar ◽  
Abdolreza Ardeshirylajimi
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Skin Diseases ◽  
Skin Disorders ◽  
Therapeutic Goals ◽  
Mesenchymal Stem Cell Therapy ◽  
Anatomy And Physiology ◽  
Concise Review

The skin is one of the crucial body organs with anatomy and physiology linked to various disorders including congenital and acquired diseases. Nowadays, mesenchymal stem cell (MSCs)- based therapy has appeared as a promising therapeutic field, in which many see opportunities to cure the costliest and incurable diseases. However, one question to be asked is that if the use of MSCs in clinical trials studies and diseases treatment has improved. In this study, the clinical trials using MSCs in skin diseases were reviewed. A remarkable number of clinical trial studies are in progress in this field; however, only a few of them have led to tangible benefits for patients. The relevant papers and ongoing clinical trials that address MSC’s therapeutic goals for various skin disorders were examined. This review can be very useful for both the dermatologists and basic skin researchers interested in contributing to stem cell-based therapeutic researches in the area of skin disorders.

Comparative Pharmacognostical Evaluation of Khadirashtaka yavakuta (Powder) and Kashaya (Decoction)

2017 ◽  
Vol 9 (10) ◽  
Author(s):  
Chandani Goswami ◽  
V. D. Hitesh Vyas ◽  
Harisha C. R.
Keyword(s):  
Dietary Habits ◽  
Prolonged Exposure ◽  
Skin Diseases ◽  
Metabolic Changes ◽  
Skin Disorders ◽  
Coarse Powder ◽  
Crude Drugs ◽  
Standard Range

Khadirashtaka Kashaya, a compound Ayurvedic formulation is prescribed mainly in the management of Kushtha Vyadhi( skin diseases), Visarp Roga (erysipelous) and Masoorika (type of measels) and it is mentioned in Sangraha Grantha like, Yogaratnakara, Gadanighraha, Bhaishajya Ratnavali. The era is rising with many of novel dietary habits and lifestyle which are ill-assorted with health. Consumption of incompatible food combinations, heavy meals; faulty temperature acclimatisation leads to several metabolic changes which results in unhealthy skin. Their prolonged exposure leads to long lasting dermatological abnormalities having vitiated Rasa and Rakta Dhatu. Khadirashtaka Kashaya helps to break the pathogenesis of skin disorders by its bitter-astringent taste, light and dry properties as well as blood purifying activity. Till date no work was found having comparatively scientifically analysed on this drug. In Present study Khadirashtaka Kashaya and Khadirashtaka choorna have been evaluated for Pharmacognostical analysis. Finished product microscopy and decoction showing the quality and genuineness of all the constituents of Khadirashtaka Kashaya (Decoction) has been done. Organoleptic features of coarse powder made out of the crude drugs were within the standard range

scholarly journals Neonatal Birthmarks at the 4 Central Hospitals in Vientiane Capital, Lao PDR

2021 ◽  
Vol 8 ◽  
pp. 2333794X2199090
Author(s):  
Vilounna Sanaphay ◽  
Sourideth Sengchanh ◽  
Alongkone Phengsavanh ◽  
Anousavanh Sanaphay ◽  
Leelawadee Techasatian
Keyword(s):  
Sebaceous Gland ◽  
Neonatal Period ◽  
Lao Pdr ◽  
Skin Lesions ◽  
Medical Advice ◽  
Point Of View ◽  
Parental Anxiety ◽  
Skin Disorders ◽  
Clinical Point ◽  
Therapeutic Procedures

Newborn skin disorders are quite common and happen to occur during the neonatal period. Most of the birthmarks are transient; however, worried parents often seek medical advice from their child’s physician regarding skin lesions. Thus, it is important to differentiate the skin lesions from pathologic ones to avoid unnecessary diagnostic or therapeutic procedures. This is the first published study in Lao neonates that carried out the data from 4 central hospitals in Vientiane Capital, Lao PDR from September 2019 to February 2020. Among 500 neonates, Sebaceous gland hyperplasia (53%), Mongolian patches (46.6%), and Erythema toxicum neonatorum (30%) were the 3 most common cutaneous conditions found in the Lao newborns. From a clinical point of view, these findings are often a source of parental anxiety and medical concern for inexperienced clinicians.

scholarly journals Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Asger S. Paludan-Müller ◽  
Perrine Créquit ◽  
Isabelle Boutron
Keyword(s):  
Clinical Trial ◽  
Clinical Trials ◽  
Clinical Study ◽  
Primary Source ◽  
European Medicines Agency ◽  
Clinical Trial Registries ◽  
Number Of Patients ◽  
Journal Publications ◽  
Clinical Study Reports ◽  
Completeness Of Reporting

Abstract Background An accurate and comprehensive assessment of harms is a fundamental part of an accurate weighing of benefits and harms of an intervention when making treatment decisions; however, harms are known to be underreported in journal publications. Therefore, we sought to compare the completeness of reporting of harm data, discrepancies in harm data reported, and the delay to access results of oncological clinical trials between three sources: clinical study reports (CSRs), clinical trial registries and journal publications. Methods We used the EMA clinical data website to identify all trials submitted to the EMA between 2015 and 2018. We retrieved all CSRs and included all phase II, II/III or III randomised controlled trials (RCTs) assessing targeted therapy and immunotherapy for cancer. We then identified related records in clinical trial registries and journals. We extracted harms data for eight pre-specified variables and determined the completeness of reporting of harm data in each of the three sources. Results We identified 42 RCTs evaluating 13 different drugs. Results were available on the EMA website in CSRs for 37 (88%) RCTs, ClinicalTrials.gov for 36 (86%), the European Clinical Trials Register (EUCTR) for 20 (48%) and in journal publications for 32 (76%). Harms reporting was more complete in CSRs than other sources. We identified marked discrepancies in harms data between sources, e.g. the number of patients discontinuing due to adverse events differed in CSRs and clinical trial registers for 88% of trials with data in both sources. For CSRs and publications, the corresponding number was 90%. The median (interquartile range) delay between the primary trial completion date and access to results was 4.34 (3.09–7.22) years for CSRs, 2.94 (1.16–4.52) years for ClinicalTrials.gov, 5.39 (4.18–7.33) years for EUCTR and 2.15 (0.64–5.04) years for publications. Conclusions Harms of recently approved oncological drugs were reported more frequently and in more detail in CSRs than in trial registries and journal publications. Systematic reviews seeking to address harms of oncological treatments should ideally use CSRs as the primary source of data; however, due to problems with access, this is currently not feasible.

Effect of Ark malahara in Vicharchika- A clinical study

2020 ◽  
Vol 6 (2) ◽  
pp. 50-54
Author(s):  
Suman Purohit ◽  
◽  
Shweta Shukla ◽  
Khemchand Sharma ◽  
◽  
...  
Keyword(s):  
Clinical Trial ◽  
Clinical Study ◽  
Medical Practice ◽  
Satisfactory Treatment ◽  
Clinical Presentations

Vicharchika (Eczema) is a type of kshudrakustha characterized with symptoms, namely, kandu, Srava, Pidaka and Shyavata and Pidikotpatti. Vicharchika is often correlated to eczema based on the clinical presentations. No satisfactory treatment is available in contemporary medical practice. In Ayurveda variousformulations are mentioned for treatment of Vicharchika. In the present study a clinical trial was done using Ark Malahara in 15 patients of either sex in between the age of 20 to 70 years. Highly significant result is obtained in Kandu, while significant result was obtained in Daha, Srava, Pidika, Rukshta, Vaivarnya.

Sign in / Sign up

Export Citation Format

Share Document